Plain-English translation of NCT04421820 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer drug called BOLD-100 in combination with a standard chemotherapy regimen called FOLFOX. The study focuses on people with advanced colorectal cancer who have already tried one prior treatment. Researchers want to see if adding this medication to the standard chemotherapy can help shrink tumors and improve outcomes while remaining safe.
Standard chemotherapy alone doesn't work for all patients, and some people's cancers stop responding to treatment over time. This trial exists to find out whether combining this medication with chemotherapy might be more effective, and whether it can be given safely alongside these strong cancer drugs.
You likely qualify if…
You likely don't qualify if…
If you qualify for the colorectal cancer arm, you'll be randomly assigned to receive either the medication at one of two dose levels plus chemotherapy, or chemotherapy alone. You'll receive the treatment through an IV and will need to attend regular clinic visits for chemotherapy doses and monitoring. Throughout the study, you'll complete quality of life questionnaires to help researchers understand how the treatment affects your day-to-day life and any nerve-related side effects.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States
Canada